The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1341
Ofatumumab (Arzerra) for CLL
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ofatumumab (Arzerra – GlaxoSmithKline), a human anti-CD20 monoclonal antibody, for treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine (Fludara, and others) and alemtuzumab (Campath). It is the second anti-CD20 antibody approved for treatment of CLL; rituximab (Rituxan), a chimeric murine/human antibody, was the first.

MECHANISM OF ACTION — CD20 antibodies bind to the CD20 antigen on B-cell lymphocytes and cause B-cell lysis.

STANDARD TREATMENT OF CLL — Initial treatment of CLL usually consists of fludarabine, cyclophosphamide (Cytoxan, and others) and rituximab (Rituxan).1 Options for patients who are refractory to initial therapy or relapse include alemtuzumab, an anti-CD52 monoclonal antibody, bendamustine (Treanda)2, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ofatumumab (Arzerra) for CLL
Article code: 1341d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian